A novel study addresses a critical yet under-explored question in cancer research: Why is aging the biggest risk factor for cancer? New preclinical model suggests blocking inflammation pathways may reverse cancer-promoting effects of aging, inspiring early-phase clinical drug trials. The study reveals how an aging immune system spurs tumor growth, offering new insights into cancer prevention and treatment, especially for older adults. In preclinical models, the research team found that anakinra, a drug typically used for inflammatory conditions such as rheumatoid arthritis, can be repurposed to block harmful signals between early lung cancer lesions and the bone marrow. This is critical, say the investigators, because as the immune system ages, it creates harmful inflammation that can drive cancer development.